By: IPP Bureau
Last updated : November 25, 2025 1:41 pm
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating
Health tech firm Neurogen Biomarking has partnered with Tasso to bring needle-free Alzheimer’s testing home.
Under the agreement, Neurogen will integrate Tasso’s virtually painless, needle-free blood collection technology into its home-based brain-health testing services.
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating. Neurogen’s platform combines blood-based biomarker tests with digital cognitive assessments, enabling earlier identification of individuals at risk for Alzheimer’s disease.
Licensed specialists will collect blood samples in patients’ homes using both Tasso+ devices and traditional draws. Samples are then analyzed in certified labs, and results reviewed by board-certified neurologists via telehealth.
“Neurogen is on a fast-track to becoming the global entry point for early Alzheimer’s evaluation,” said Dr Rany Aburashed, CEO and Founder of Neurogen Biomarking. “Tasso’s technology makes the testing process streamlined, scalable, and accessible—bringing a patient-centric approach to Alzheimer’s care.”
Recent research presented at the 2025 Alzheimer’s Association International Conference (AAIC) confirmed that Tasso’s devices deliver high-quality samples suitable for biomarker analysis.
The study, led by Dr Elisabeth Thijssen, Neurogen’s Chief Scientific Officer, highlighted the platform’s integrated model of home sample collection, cognitive assessment, and virtual neurologist consultation. Findings showed a strong correlation between Tasso-collected samples and traditional venipuncture, validating its use within Neurogen’s workflow.
“Making blood collection patient-centric is essential to improving access,” said Ben Casavant, CEO and Co-Founder of Tasso. “Our technology offers a simple, comfortable way for individuals to provide blood samples, and we’re proud to see it integrated into Neurogen’s innovative service model.”
The need for faster, more accessible testing is urgent. On average, patients wait 45 to 50 months between their first primary care visit and a neurology appointment—delays that can make early intervention impossible. Neurogen’s platform, currently in beta, can reduce that timeline to just five to seven months.
With more than 16 million Americans aged 65 and older experiencing memory impairment—and fewer than 8% receiving a formal diagnosis—this partnership addresses a critical gap in early detection and care. As the aging population grows and new diagnostic tools emerge, Neurogen and Tasso aim to redefine how Alzheimer’s and cognitive decline are detected, diagnosed, and managed.